Hospital

Empagliflozin (Jardiance, Boehringer Ingelheim/Lilly) tablets are the first and only heart failure therapy to demonstrate a statistically significant risk reduction in cardiovascular death.

Session explores data from both the SCORED trial of sotagliflozin and the REVERSE-IT trial investigating bentracimab to reverse the antiplatelet effects of ticagrelor.

Health care professionals need to meet their patients at their health level and find a diet and medication regimen that works for them to best reduce the risk of cardiovascular events.

Lowering salt intake was not found to reduce visits to the emergency department, however, there were improvements in quality of life.

Sarah Wheeler, PharmD, BCOP, clinical pharmacy specialist in Hematology/Oncology at UF Health Shands Cancer Hospital, discusses some of the barriers that patients with cancer may encounter following their diagnosis.

Session at the Hematology/Oncology Pharmacy Association Annual Conference 2022 focuses on methods to improve emotional exhaustion among pharmacists and other health care providers.

Rucaparib (Rubraca) significantly improved progression-free survival when administered as maintenance treatment in newly diagnosed patients with advanced ovarian cancer.

Ted Okon, MBA, executive director of the Community Oncology Alliance (COA), discusses key highlights from the in-person COA 2022 conference.

21-gene profiling is also preferred for patients with 1 to 3 pathologically positive lymph nodes, according to a presentation at the Hematology/Oncology Pharmacy Association conference.

Christy S. Harris, PharmD, BCOP, FHOPA, clinical pharmacy specialist at Dana-Farber Cancer Institute, discusses guidelines for common therapies and appropriate monitoring recommendations for selected therapies used in the treatment of adult sarcomas.

Triumeq is a tablet containing 50 mg of dolutegravir, 600 mg of abacavir, and 300 mg of lamivudine.

Heidi D. Finnes, PharmD, BCOP, FHOPA, president-elect of Hematology/Oncology Pharmacy Association (HOPA), discusses ways to address burnout in the hematology/oncology space.

FDA to evaluate New Drug Application for futibatinib in the treatment of patients with previously treated locally advanced or metastatic cholangiocarcinoma.

The Roche subsidiary reports that it will continue to evaluate tiragolumab plus Tecentriq and chemotherapy in non-small cell lung cancer and other cancer types through more phase 3 trials.

Heidi D. Finnes, PharmD, BCOP, FHOPA, president-elect of Hematology/Oncology Pharmacy Association (HOPA), provides details of the upcoming HOPA 2022 conference.

ImmunoGen, Inc submits Biologics License Application under the accelerated approval pathway for mirvetuximab soravtansine monotherapy for patients with FRα-high platinum-resistant ovarian cancer previously treated with 1 to 3 prior systemic treatments.

They are also at greater risk of death than men when undergoing cardiac procedures, a new analysis shows.

Analysis from the American Society of Health-System Pharmacists indicates turnover rates of at least 21% in 2021.

FDA approves expanded indication for the treatment of HIV-1 in virologically suppressed adolescents 12 years of age or older, who weigh at least 35 kg, and who are on a stable antiretroviral regimen, with no history of treatment failure or known or suspected resistance to either cabotegravir or rilpivirine.

Veyonda, a novel proprietary formulation of idronoxil, is a first-in-class, dual-acting oncotoxic and immuno-oncology molecule.

Elizabeth Spurlock, MA, PHR, director of HR Business Partner at Texas Oncology, discusses how burnout among physicians, nurses, and hospital administrators has impacted the role of the pharmacist in patient care.

Heidi D. Finnes, PharmD, BCOP, FHOPA, president-elect of Hematology/Oncology Pharmacy Association (HOPA), provides details of the upcoming HOPA 2022 conference.

An 11-fold increase in geometric mean neutralizing antibody titers was reported at 2 weeks after the second booster compared to 5 months after the first booster dose.

Patient treatment improves and medication prices decline as a result, a new analysis indicates.

RBX2660, a standardized, stabilized, novel microbiota-based live therapeutic, shows promise treating patients with recurrent Clostridium difficile infection.

Ibalizumab-uiyk (Trogarzo) is a CD4-directed post-attachment HIV-1 inhibitor.

Abemaciclib (Verzenio; Lilly) is the first addition to adjuvant endocrine therapy approved by the FDA in two decades.

Access to buprenorphine among Medicaid beneficiaries was not affected during the pandemic.